Several pharmaceutical companies in the US take issue with his refusal to sell his potential vaccine at cost. American companies Pfizer, Merck and Moder
Several pharmaceutical companies in the US take issue with his refusal to sell his potential vaccine at cost.
The US companies Pfizer, Merck and Moderna confirmed this Tuesday that they do not sell their potential coronavirus vaccines at cost, at a hearing in the US Congress. On the other hand, Johnson & Johnson and AstraZeneca intend to initially sell their vaccines without making a profit.
Several companies have received grants of hundreds of millions of dollars from the US government or from other countries, but these contracts are not always accompanied by clauses that limit the final cost of the doses.
READ ALSO >> Covid-19: two vaccine projects generate an immune response”
Summer offer: Take advantage of a special offer of 2 months for €1 I subscribe
“We are not going to sell at cost,” Moderna chairman Stephen Hoge said in response to a question from a member of parliament. Biotech has developed one of the most advanced experimental vaccines, with full Phase 3 trials scheduled to begin next week in 30,000 volunteers. It received $483 million of US public money to fund research and development, but no contracts to supply the United States, Stephen Hoge said.
“This is an extraordinary period and our price will reflect it”
“No, we will not sell at cost,” said Julie Gerberding of Merck, which will not have a vaccine ready until 2021 at the earliest and has not signed a supply deal with Washington. “This is an extraordinary period and our pricing will reflect that,” added John Young, Pfizer. “During the pandemic, we will price our potential vaccine taking into account the current global health situation.”
READ ALSO >> Covid-19: how France wasted the Institut Pasteur vaccine, the United States
But AstraZeneca, Oxford University’s partner in the development of the most advanced vaccine, which is already in Phase 3, signed a $1.2 billion deal with the US government agency Barda, which includes the supply of $300 million. of doses at cost. The European Union signed a similar agreement in June.
Read our full file
Vaccines: legal obligations, mistrust and growing shortages
Covid vaccine: why you should be wary of the effects of ads Covid-19: Moderna’s vaccine in final phase of clinical trial July 27 Covid-19: NGOs warn against “vaccine nationalism”
Johnson & Johnson, also funded by the White House’s “Operation Warp Speed” ($456 million), said separately that the cost of more than a billion doses would not generate revenue during the emergency phase of the pandemic.
Date Updated: July 21, 2020, 7:58 PM
Categories: Optical Illusion
Source: newstars.edu.vn